Search results
Showing 1 to 15 of 16 results for omalizumab
TA ID Appraisal Short title TA201 Asthma (in children) - omalizumab TA265 Bone metastases from solid tumours - denosumab TA566
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)
NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA678
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)
NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
'Life changing' treatment approved for people with severe asthma
Omalizumab (Xolair) is now available for NHS patients as an add-on treatment for severe, persistent allergic asthma in adults, adolescents and children, says NICE.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)
This guidance has been updated and replaced by NICE technology appraisal guidance 278.
This guidance has been replaced by NICE technology appraisal guidance 278.